Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 13.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with obesity, defined as a Body Mass Index greater than or equal to 30.0 kg/m2~* Stable body weight, defined as \<5 kg change (per participant report) for 90 days before visit 1~Exclusion Criteria:~* Any condition possibly affecting drug absorption~* Current or prior diagnosis of Type 1 or Type 2 diabetes mellitus or secondary forms of diabetes~* History of myocardial infarction, unstable angina, arterial revascularization, stroke, heart failure, or transient ischemic attack within 6 months prior to visit 1~* Any malignancy not considered cured~* Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 or suspected MTC~* History of acute pancreatitis within 180 days (6 months) prior to visit 1 or any history of chronic pancreatitis~* Symptomatic gallbladder disease~* Medical history or characteristics suggestive of genetic or syndromic obesity or obesity induced by other endocrinological disorders~* History of major depressive disorder or other severe psychiatric disorders within the last 2 years~* Any lifetime history of a suicide attempt~* Known medical history of active liver disease, including chronic active hepatitis B or C, or primary biliary cirrhosis~* Known history of HIV~* Supine blood pressure greater than or equal to 160 mmHg (systolic) or greater than or equal to 100 mmHg (diastolic)~* Clinically relevant ECG abnormalities~* Positive urine drug screen~* Participation in a formal weight reduction program within 90 days prior to visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Cohorts 1 and 2) (Type: PLACEBO_COMPARATOR): None
- PF-06882961 40 milligrams (mg) twice daily (BID), 1-week titration (Cohort 1) (Type: EXPERIMENTAL): The dose will be titrated with 1 week of dosing at each step to reach the target dose of 40 mg BID.
- PF-06882961 80 mg BID, 1-week titration (Cohort 1) (Type: EXPERIMENTAL): The dose will be titrated with 1 week of dosing at each step to reach the target dose of 80 mg BID.
- PF-06882961 120 mg BID, 1-week titration (Cohort 1) (Type: EXPERIMENTAL): The dose will be titrated with 1 week of dosing at each step to reach the target dose of 120 mg BID.
- PF-06882961 160 mg BID, 1-week titration (Cohort 1) (Type: EXPERIMENTAL): The dose will be titrated with 1 week of dosing at each step to reach the target dose of 160 mg BID.
- PF-06882961 200 mg BID, 1-week titration (Cohort 1) (Type: EXPERIMENTAL): The dose will be titrated with 1 week of dosing at each step to reach the target dose of 200 mg BID.
- PF-06882961 120 mg BID, 2-week titration (Cohorts 1 and 2) (Type: EXPERIMENTAL): The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 120 mg BID.
- PF-06882961 160 mg BID, 2-week titration (Cohorts 1 and 2) (Type: EXPERIMENTAL): The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 160 mg BID.
- PF-06882961 200 mg BID, 2-week titration (Cohorts 1 and 2) (Type: EXPERIMENTAL): The dose will be titrated with 2 weeks of dosing at each step to reach the target dose of 200 mg BID.
- Placebo (Cohort 3) (Type: PLACEBO_COMPARATOR): None
- PF-06882961 80 mg BID, 4-week titration (Cohort 3) (Type: EXPERIMENTAL): The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 80 mg BID.
- PF-06882961 140 mg BID, 4-week titration (Cohort 3) (Type: EXPERIMENTAL): The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 140 mg BID.
- PF-06882961 200 mg BID, 4-week titration (Cohort 3) (Type: EXPERIMENTAL): The dose will be titrated with 4 weeks of dosing at each step to reach the target dose of 200 mg BID.

Based on this trial design, predict the completion outcome and termination type (if applicable).